Harbin Medisan Pharmaceutical Co (SZSE:002900) Accounts Payable & Accrued Expense : ¥292 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co Accounts Payable & Accrued Expense?

Harbin Medisan Pharmaceutical Co's quarterly accounts payable & accrued expense declined from Sep. 2023 (¥340 Mil) to Dec. 2023 (¥314 Mil) and declined from Dec. 2023 (¥314 Mil) to Mar. 2024 (¥292 Mil).

Harbin Medisan Pharmaceutical Co's annual accounts payable & accrued expense increased from Dec. 2021 (¥238 Mil) to Dec. 2022 (¥295 Mil) and increased from Dec. 2022 (¥295 Mil) to Dec. 2023 (¥314 Mil).

Harbin Medisan Pharmaceutical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co Accounts Payable & Accrued Expense Chart

Harbin Medisan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

446.61

297.56

238.23

294.65

313.65

Harbin Medisan Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															342.23	348.14	339.77	313.65	292.02

Harbin Medisan Pharmaceutical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

N/A

Address

Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025

Website

http://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.

Executives

Fan Qing Ji	Executives
Zhao Qing Fu	Directors, Directors, and Executives
Liang Yan Fei	Directors, executives
Yao Fa Xiang	Executives
Wang Ming Xin	Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines